Skip to main content

Drug Interactions between deferasirox and oxtriphylline

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

oxtriphylline deferasirox

Applies to: oxtriphylline and deferasirox

GENERALLY AVOID: Coadministration with deferasirox may significantly increase the plasma concentrations of theophylline. The proposed mechanism is deferasirox inhibition of CYP450 1A2, the isoenzyme primarily responsible for the metabolic clearance of theophylline. In a study of healthy volunteers, administration of a single 120 mg dose of theophylline in combination with deferasirox (repeated dosing of 30 mg/kg/day) resulted in an approximate doubling of theophylline systemic exposure (AUC) and elimination half-life. The single-dose peak plasma concentration (Cmax) was not affected, but an increase in theophylline Cmax is expected to occur with chronic dosing.

MANAGEMENT: Given the potential risk for theophylline toxicity, concomitant use with deferasirox should generally be avoided. Dosage adjustment for theophylline may be needed if coadministration with deferasirox is required. Close monitoring of serum theophylline levels is recommended, particularly following the addition, discontinuation, or change of dosage of deferasirox. Patients should be advised to notify their physician if they experience signs of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, palpitations, and cardiac arrhythmia.

References

  1. (2005) "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals

Switch to consumer interaction data

Drug and food interactions

Moderate

deferasirox food

Applies to: deferasirox

ADJUST DOSING INTERVAL: According to product labeling, the bioavailability of deferasirox was variably increased when taken with a meal.

MANAGEMENT: To ensure consistent plasma drug levels, deferasirox should be taken on an empty stomach 30 minutes before eating preferably at the same time everyday.

References

  1. (2005) "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer